Tokyo, Nov. 14 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000059765) titled 'Burden of disease study in migraine patients in Japan' on Nov. 13.
Study Type:
Observational
Primary Sponsor:
Institute - AbbVie GK
Condition:
Condition - Migraine
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - To describe the disease burden in Japanese migraine patients who present to the medical facility that meets the requirements specified in the Optimal Clinical Use Guidelines (OUG) for the use of anti-Calcitonin Gene-Related Peptide (CGRP) antibodies (OUG facility) or Non-OUG facility
Basic objectives2 - Others
Eligibility:
Age-lower limit - 15
years-old
<=
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - 1.15 years old or more at survey
2.Japan citizen
3.Physician confirmed diagnosis of migraine based on International Classification of Headache Disorders, 3rd edition (ICHD-3) criteria
4.Patients who have given informed consent for participation in this study
Key exclusion criteria - 1.Unable to respond to the questionnaire by oneself
Target Size - 400
Recruitment Status:
Recruitment status - Preinitiation
Date of protocol fixation - 2025 Year 09 Month 30 Day
Anticipated trial start date - 2025 Year 12 Month 01 Day
Last follow-up date - 2026 Year 06 Month 30 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000068342
Disclaimer: Curated by HT Syndication.
